Camlin Fine Sciences Ltd

- No major capital expenditure is planned for FY '24; the company intends to fund maintenance capex (~INR 20-30 crores) through internal accruals. - For working capital, an initial requirement of INR 20-30 crores is expected in the first half of FY '24, which will taper down by year-end. - The company holds a USD 15 million FCCB (Foreign Currency Convertible Bond) option with IFC, likely to be converted at INR 105 crores, which would reduce debt by around INR 115-120 crores. - No specific mention of new fundraising through fresh debt or equity was made during the call. - Overall, operational cash flows are expected to improve, supporting debt reduction without the need for significant external borrowing or equity issuance in FY '24.

- No major capex planned for FY '24; focus on utilizing internal accruals for maintenance capex (~INR 20-30 crores per annum). - Working capital requirement may increase by INR 20-30 crores in the first 6 months but expected to taper off by year-end FY '24. - Discussions in FY '24 about potentially building a new plant to meet demand beyond current capacity (~800 tons/year). - Expansion priorities in next 2-3 years include growing diphenol downstream products, Aroma business (vanillin, heliotropin), blend business (natural products), and scaling up Omega-3 fatty acid business. - Vanillin plant commissioned and ramping up; expected to reach near 100% capacity by end of FY '23 but market demand will dictate actual production. - Growth driven more by capacity utilization and market demand than new large-capex initiatives currently.

- Expecting revenue growth of about 25% per year over the next few years (Page 14). - FY '24 projected to see growth in revenue around 30% to 35% compared to FY '23 (Page 4, 11). - Volume growth expected despite price corrections and softer chemical prices (Page 13). - Vanillin plant ramp-up: gradual scaling with commercial realization starting Q1 FY '24; full market penetration over two years (Page 10-11, 15). - Targeting at least 50% global market share in MEHQ in the next 2 years, with other HQ downstream products also scaling up (Page 12-13). - Continued growth in blend business at about 30% per year (Page 5). - Opportunities in specialty natural products and Omega 3 fatty acids expansion planned in next 3-4 years (Page 5). - Capacity constraints likely to be addressed in FY '24 with discussions for next plant building underway (Page 14).

- The company expects revenue growth of about 25-35% annually for FY 2024 and FY 2025. - EBITDA margins are projected to expand, driven by scaling up vanillin production and improved yields/processes. - Vanillin plant ramp-up to 100% production by end of FY 2023, contributing margin accretive revenues starting FY 2024. - Growth drivers also include increased focus on HQ downstream products like MEHQ, HQEE, para-benzoquinone, and naphthol IRG from FY 2024 onwards. - Internal cost mitigation programs aim to reduce fixed operating costs by 20%, aiding margin improvement. - No major capex planned immediately; expansion to be funded via internal accruals. - Lockheed Martin order post FY 2024 could contribute significantly (over 10-15% of business) depending on market success. - Despite market price corrections, volume growth and new products expected to sustain profit growth.

- The company has new orders lining up from Q2 FY '24 onwards, indicating an expected increase in order inflow. - For Lockheed Martin, the first commercial order is on track for delivery by Q2 FY '24, with further orders under discussion contingent upon product market success. - The capacities, especially for Lockheed Martin order, are limited right now (around 800 tons/year), expected to fill up by FY '25, prompting discussions for potential new plant construction during FY '24. - Vanillin is in the sampling phase, with supply expected to start before the end of FY '23 and real production ramping up from Q1 FY '24. - MEHQ and other downstream products like HQEE, para-benzoquinone, and naphthol IRG are areas of focus for growth, with increasing production planned within available and identified capacities. - The management expects substantial traction in these product lines in FY '24 and FY '25.